Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Unilateral HER2 Positive Breast Cancer
Interventions: DRUG: Afatinib|DRUG: Trastuzumab|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: German Breast Group
Collaborators: Boehringer Ingelheim